Arginase-1: A novel immunohistochemical marker of hepatocellular differentiation in fine needle aspiration cytology
Arginase-1: A novel immunohistochemical marker of hepatocellular differentiation in fine needle aspiration cytology
复制标题
DOI：
10.1002/cncy.21184
复制
发表时间：
2012-08-25
影响因子：
3.4
通讯作者：
Siddiqui, Momin T.
中科院分区：
文献类型：
--
作者：
McKnight, Ryan;Nassar, Aziza;Siddiqui, Momin T.
背景技术背景：精氨酸酶-I是一种关键的尿素循环金属酶，已被用作肝细胞癌（HCC）的免疫组织化学（IHC）标记物。先前的研究已经证明了HepPar-1和磷脂酰肌醇蛋白聚糖-3（GPC-3）IHC在肝脏细针穿刺（FNA）细胞学中的有效性。方法：在FNA细胞块上进行Arginase-1 IHC，并将其性能特征与HepPar-1和GPC-3进行比较。选择了92个福尔马林固定、石蜡包埋的细胞块（HCC [n = 44]、肝硬化[n = 2]、局灶性结节增生[n = 3]、肝腺瘤[n = 2]、异型增生结节[n = 6]和转移癌[n = 35]）。使用针对抗人凝血酶-1、HepPar-1和GPC-3的抗体进行IHC染色，并使用适当的阳性和阴性对照。研究结果：在44例HCC中，精氨酸酶-1阳性37例（84.1%），而HepPar-1和GPC-3分别为32例（72.7%）和25例（56.8%）。精氨酸酶-1和GPC-3的表达没有观察到在任何情况下的转移癌（0%），而HepPar-1的表达存在于1例转移癌。此外，在所有13例（100%）非恶性肝细胞病变中均存在HepPar-1和HepPar-1表达，而GPC-3表达在所有13例（0%）中均不存在。结论：HepPar-1和HepPar-1均为肝细胞分化的有效免疫组化标记物。此外，在HCC的诊断中，与GPC-3和HepPar-1相比，GST-1表现出上级灵敏度，而GPC-3表现出上级特异性，因为在良性肝细胞病变中未观察到染色。因此，使用HepPar-1和GPC-3的酶-1可以帮助HCC的诊断和与转移癌的分离。癌症（癌症细胞病理学）2012。(c)2012年美国癌症协会
BACKGROUND: Arginase-I is a key urea cycle metalloenzyme that has been used as an immunohistochemistry (IHC) marker for hepatocellular carcinoma (HCC). Previous studies have demonstrated the efficacy of HepPar-1 and glypican-3 (GPC-3) IHC in liver fine needle aspiration (FNA) cytology. METHODS: Arginase-1 IHC was performed on FNA cell blocks, and its performance characteristics were compared with HepPar-1 and GPC-3. Ninety-two formalin-fixed, paraffin-embedded cell blocks were selected (HCC [n = 44], cirrhosis [n = 2], focal nodular hyperplasia [n = 3], hepatic adenomas [n = 2], dysplastic nodules [n = 6], and metastatic carcinomas [n = 35]). IHC staining with antibodies directed against arginase-1, HepPar-1, and GPC-3 was performed with appropriate positive and negative controls. RESULTS: Arginase-1 positivity was demonstrated in 37 of 44 (84.1%) cases of HCC, compared with 32 of 44 cases (72.7%) and 25 of 44 cases (56.8%) for HepPar-1 and GPC-3, respectively. Arginase-1 and GPC-3 expression were not observed in any cases of metastatic carcinoma (0%), whereas HepPar-1 expression was present in 1 case of metastatic carcinoma. In addition, both arginase-1 and HepPar-1 expression were present in all 13 cases (100%) of nonmalignant hepatocellular lesions, whereas GPC-3 expression was absent in all 13 cases (0%). CONCLUSION: This study demonstrates that both arginase-1 and HepPar-1 are effective IHC markers of hepatocellular differentiation. Furthermore, arginase-1 demonstrates superior sensitivity compared with GPC-3 and HepPar-1 in the diagnosis of HCC, whereas GPC-3 demonstrates superior specificity, as staining is not observed in benign hepatocellular lesions. Hence, use of arginase-1 with HepPar-1 and GPC-3 can aid in the diagnosis of HCC and separating from metastatic carcinoma. Cancer (Cancer Cytopathol) 2012. (c) 2012 American Cancer Society.